Immunological Impact of a Post Cell Therapy Treatment With FLT3 Inhibitors
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NICE · May 23, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring the effects of a medication called Gilteritinib in patients who have received a special type of treatment known as allogeneic stem cell transplantation (aHSCT) for acute myeloid leukemia (AML). AML is a type of blood cancer, and aHSCT is often the only way to potentially cure it. However, many patients can relapse, which means the cancer comes back after treatment. The goal of this study is to better understand how Gilteritinib affects the immune system and whether it can help prevent this relapse without causing other serious health issues.
To be eligible for this trial, participants must be over 18 years old, have received aHSCT for AML, and be set to receive Gilteritinib as part of their ongoing treatment. Those with certain health conditions or who are pregnant, among other criteria, will not be able to participate. If you join this study, you can expect to undergo some tests and evaluations to help researchers gather information on how Gilteritinib interacts with immune cells in the body over the next three years. This research could lead to new ways to improve treatment and reduce the chances of cancer coming back after transplantation.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient \> 18y/o
- • Patient who received an allogeneic stem cell transplantation for an acute myeloid leukemia and who will receive gilteritinib as post transplantation maintenance
- • Matched related, matched unrelated, mismatched unrelated and haploidentical donors
- Exclusion Criteria:
- • Minors
- • Pregnant women
- • Patient under 'tutelle', 'curatelle' or in prison
- • Patient who has been treated for a solid tumor in the past 2 years
- • Known human immunodeficiency virus (HIV) infection or HIV-related malignancy
- • Clinically active hepatitis B or hepatitis C infection
- • Known allergy or hypersensitivity to gilteritinib
About Centre Hospitalier Universitaire De Nice
The Centre Hospitalier Universitaire (CHU) de Nice is a leading academic medical center located in Nice, France, dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHU de Nice is committed to enhancing patient care by conducting rigorous studies that explore new therapies and treatment modalities across various medical disciplines. With a focus on collaboration, the center integrates cutting-edge technology and interdisciplinary expertise to ensure the highest standards of research integrity and patient safety. CHU de Nice plays a vital role in the development of evidence-based medicine, contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nice, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported